January 1, 2017Open Access
Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis
Key Points
Key points are not available for this paper at this time.
Abstract
Pioglitazone was associated with reduced risk of MACE in people with insulin resistance, pre-diabetes and diabetes mellitus. However, the risks of heart failure, bone fracture, oedema and weight gain were increased.
Cite This Study
Liao et al. (Sun,) studied this question.